vs
Side-by-side financial comparison of AMICUS THERAPEUTICS, INC. (FOLD) and WYNDHAM HOTELS & RESORTS, INC. (WH). Click either name above to swap in a different company.
WYNDHAM HOTELS & RESORTS, INC. is the larger business by last-quarter revenue ($334.0M vs $185.2M, roughly 1.8× AMICUS THERAPEUTICS, INC.). AMICUS THERAPEUTICS, INC. runs the higher net margin — 0.9% vs -18.0%, a 18.9% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs -76.3%). WYNDHAM HOTELS & RESORTS, INC. produced more free cash flow last quarter ($168.0M vs $16.0M). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs -4.6%).
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
Wyndham Hotels & Resorts, Inc., is an American hospitality company based in Parsippany, New Jersey, United States. It describes itself as the largest hotel franchisor in the world, with 9,100 locations.
FOLD vs WH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $185.2M | $334.0M |
| Net Profit | $1.7M | $-60.0M |
| Gross Margin | 85.7% | — |
| Operating Margin | 8.6% | — |
| Net Margin | 0.9% | -18.0% |
| Revenue YoY | 23.7% | -76.3% |
| Net Profit YoY | -88.5% | -170.6% |
| EPS (diluted) | $0.00 | $-0.80 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $334.0M | ||
| Q4 25 | $185.2M | $334.0M | ||
| Q3 25 | $169.1M | $382.0M | ||
| Q2 25 | $154.7M | $397.0M | ||
| Q1 25 | $125.2M | $316.0M | ||
| Q4 24 | $149.7M | $336.0M | ||
| Q3 24 | $141.5M | $396.0M | ||
| Q2 24 | $126.7M | $367.0M |
| Q1 26 | — | $-60.0M | ||
| Q4 25 | $1.7M | $-60.0M | ||
| Q3 25 | $17.3M | $105.0M | ||
| Q2 25 | $-24.4M | $87.0M | ||
| Q1 25 | $-21.7M | $61.0M | ||
| Q4 24 | $14.7M | $85.0M | ||
| Q3 24 | $-6.7M | $102.0M | ||
| Q2 24 | $-15.7M | $86.0M |
| Q1 26 | — | — | ||
| Q4 25 | 85.7% | — | ||
| Q3 25 | 88.5% | — | ||
| Q2 25 | 90.2% | — | ||
| Q1 25 | 90.7% | — | ||
| Q4 24 | 90.1% | — | ||
| Q3 24 | 90.6% | — | ||
| Q2 24 | 91.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | 8.6% | -11.4% | ||
| Q3 25 | 20.3% | 46.6% | ||
| Q2 25 | -6.1% | 37.8% | ||
| Q1 25 | -6.3% | 35.4% | ||
| Q4 24 | 10.7% | 38.4% | ||
| Q3 24 | 15.3% | 43.2% | ||
| Q2 24 | 11.8% | 39.5% |
| Q1 26 | — | -18.0% | ||
| Q4 25 | 0.9% | -18.0% | ||
| Q3 25 | 10.2% | 27.5% | ||
| Q2 25 | -15.8% | 21.9% | ||
| Q1 25 | -17.3% | 19.3% | ||
| Q4 24 | 9.8% | 25.3% | ||
| Q3 24 | -4.8% | 25.8% | ||
| Q2 24 | -12.4% | 23.4% |
| Q1 26 | — | $-0.80 | ||
| Q4 25 | $0.00 | $-0.77 | ||
| Q3 25 | $0.06 | $1.36 | ||
| Q2 25 | $-0.08 | $1.13 | ||
| Q1 25 | $-0.07 | $0.78 | ||
| Q4 24 | $0.05 | $1.06 | ||
| Q3 24 | $-0.02 | $1.29 | ||
| Q2 24 | $-0.05 | $1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $293.5M | $64.0M |
| Total DebtLower is stronger | $392.7M | — |
| Stockholders' EquityBook value | $274.2M | $468.0M |
| Total Assets | $949.9M | $4.2B |
| Debt / EquityLower = less leverage | 1.43× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $64.0M | ||
| Q4 25 | $293.5M | $64.0M | ||
| Q3 25 | $263.8M | $70.0M | ||
| Q2 25 | $231.0M | $50.0M | ||
| Q1 25 | $250.6M | $48.0M | ||
| Q4 24 | $249.9M | $103.0M | ||
| Q3 24 | $249.8M | $72.0M | ||
| Q2 24 | $260.1M | $70.0M |
| Q1 26 | — | — | ||
| Q4 25 | $392.7M | $2.5B | ||
| Q3 25 | $392.0M | $2.6B | ||
| Q2 25 | $391.3M | $2.5B | ||
| Q1 25 | $390.7M | $2.5B | ||
| Q4 24 | $390.1M | $2.4B | ||
| Q3 24 | $389.5M | $2.4B | ||
| Q2 24 | $388.9M | $2.4B |
| Q1 26 | — | $468.0M | ||
| Q4 25 | $274.2M | $468.0M | ||
| Q3 25 | $230.4M | $583.0M | ||
| Q2 25 | $204.3M | $570.0M | ||
| Q1 25 | $193.6M | $579.0M | ||
| Q4 24 | $194.0M | $650.0M | ||
| Q3 24 | $178.8M | $583.0M | ||
| Q2 24 | $132.5M | $623.0M |
| Q1 26 | — | $4.2B | ||
| Q4 25 | $949.9M | $4.2B | ||
| Q3 25 | $868.8M | $4.3B | ||
| Q2 25 | $815.3M | $4.3B | ||
| Q1 25 | $789.8M | $4.2B | ||
| Q4 24 | $785.0M | $4.2B | ||
| Q3 24 | $786.6M | $4.2B | ||
| Q2 24 | $749.5M | $4.2B |
| Q1 26 | — | — | ||
| Q4 25 | 1.43× | 5.37× | ||
| Q3 25 | 1.70× | 4.43× | ||
| Q2 25 | 1.92× | 4.44× | ||
| Q1 25 | 2.02× | 4.29× | ||
| Q4 24 | 2.01× | 3.72× | ||
| Q3 24 | 2.18× | 4.19× | ||
| Q2 24 | 2.93× | 3.83× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.3M | $367.0M |
| Free Cash FlowOCF − Capex | $16.0M | $168.0M |
| FCF MarginFCF / Revenue | 8.6% | 50.3% |
| Capex IntensityCapex / Revenue | 0.2% | — |
| Cash ConversionOCF / Net Profit | 9.62× | — |
| TTM Free Cash FlowTrailing 4 quarters | $29.8M | $437.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $367.0M | ||
| Q4 25 | $16.3M | $152.0M | ||
| Q3 25 | $35.7M | $86.0M | ||
| Q2 25 | $-26.5M | $70.0M | ||
| Q1 25 | $7.8M | $59.0M | ||
| Q4 24 | $-3.9M | $134.0M | ||
| Q3 24 | $-23.0M | $79.0M | ||
| Q2 24 | $22.7M | $1.0M |
| Q1 26 | — | $168.0M | ||
| Q4 25 | $16.0M | $136.0M | ||
| Q3 25 | $35.3M | $75.0M | ||
| Q2 25 | $-28.9M | $58.0M | ||
| Q1 25 | $7.5M | $52.0M | ||
| Q4 24 | $-4.2M | $109.0M | ||
| Q3 24 | $-23.3M | $71.0M | ||
| Q2 24 | $21.6M | $-6.0M |
| Q1 26 | — | 50.3% | ||
| Q4 25 | 8.6% | 40.7% | ||
| Q3 25 | 20.9% | 19.6% | ||
| Q2 25 | -18.7% | 14.6% | ||
| Q1 25 | 6.0% | 16.5% | ||
| Q4 24 | -2.8% | 32.4% | ||
| Q3 24 | -16.5% | 17.9% | ||
| Q2 24 | 17.0% | -1.6% |
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 4.8% | ||
| Q3 25 | 0.2% | 2.9% | ||
| Q2 25 | 1.6% | 3.0% | ||
| Q1 25 | 0.2% | 2.2% | ||
| Q4 24 | 0.2% | 7.4% | ||
| Q3 24 | 0.3% | 2.0% | ||
| Q2 24 | 0.9% | 1.9% |
| Q1 26 | — | — | ||
| Q4 25 | 9.62× | — | ||
| Q3 25 | 2.06× | 0.82× | ||
| Q2 25 | — | 0.80× | ||
| Q1 25 | — | 0.97× | ||
| Q4 24 | -0.27× | 1.58× | ||
| Q3 24 | — | 0.77× | ||
| Q2 24 | — | 0.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
WH
| Fee-related and other revenues | $334.0M | 100% |
| Management and other fees | $2.0M | 1% |
